Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Medtronic
Daiichi Sankyo
Harvard Business School
Moodys
QuintilesIMS
Colorcon
Farmers Insurance
Citi
US Army

Generated: August 22, 2017

DrugPatentWatch Database Preview

LONSURF Drug Profile

« Back to Dashboard

What is the patent landscape for Lonsurf, and what generic Lonsurf alternatives are available?

Lonsurf is a drug marketed by Taiho Oncology and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-eight patent family members in twenty countries.

The generic ingredient in LONSURF is tipiracil hydrochloride; trifluridine. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the tipiracil hydrochloride; trifluridine profile page.

Summary for Tradename: LONSURF

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list5
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:LONSURF at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taiho Oncology
LONSURF
tipiracil hydrochloride; trifluridine
TABLET;ORAL207981-001Sep 22, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Taiho Oncology
LONSURF
tipiracil hydrochloride; trifluridine
TABLET;ORAL207981-002Sep 22, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Taiho Oncology
LONSURF
tipiracil hydrochloride; trifluridine
TABLET;ORAL207981-001Sep 22, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Taiho Oncology
LONSURF
tipiracil hydrochloride; trifluridine
TABLET;ORAL207981-002Sep 22, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Taiho Oncology
LONSURF
tipiracil hydrochloride; trifluridine
TABLET;ORAL207981-001Sep 22, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LONSURF

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Taiho Oncology
LONSURF
tipiracil hydrochloride; trifluridine
TABLET;ORAL207981-001Sep 22, 2015► Subscribe► Subscribe
Taiho Oncology
LONSURF
tipiracil hydrochloride; trifluridine
TABLET;ORAL207981-002Sep 22, 2015► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: LONSURF

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,799,783Method of administrating an anticancer drug containing .alpha., .alpha., .alpha.-trifluorothymidine and thymidine phosphorylase inhibitor► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LONSURF

Country Document Number Estimated Expiration
Australia3192800► Subscribe
Japan2000273044► Subscribe
South Korea20160020560► Subscribe
Denmark1080726► Subscribe
World Intellectual Property Organization (WIPO)2014203877► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Merck
Citi
Fish and Richardson
McKinsey
Argus Health
Deloitte
US Department of Justice
Cerilliant
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot